Compare HNI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HNI | CRVS |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 1.2B |
| IPO Year | 1994 | 2016 |
| Metric | HNI | CRVS |
|---|---|---|
| Price | $36.30 | $15.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $70.00 | $28.20 |
| AVG Volume (30 Days) | 718.3K | ★ 996.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ 1.11 | N/A |
| Revenue | ★ $2,839,000,000.00 | N/A |
| Revenue This Year | $117.19 | N/A |
| Revenue Next Year | $3.68 | N/A |
| P/E Ratio | $31.69 | ★ N/A |
| Revenue Growth | ★ 12.37 | N/A |
| 52 Week Low | $31.41 | $3.11 |
| 52 Week High | $53.29 | $26.95 |
| Indicator | HNI | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.10 | 52.16 |
| Support Level | $33.72 | $6.65 |
| Resistance Level | $47.41 | $18.73 |
| Average True Range (ATR) | 1.17 | 0.90 |
| MACD | 0.68 | 0.24 |
| Stochastic Oscillator | 92.67 | 76.79 |
HNI Corp is a provider of commercial furnishings and hearth products. Its two reportable segments are workplace furnishings and residential building products. The workplace furnishings segment includes furniture systems, seating, storage, tables, architectural products, ancillary products, and hospitality products. The residential building products segment includes various gas, wood, electric, and pellet-fueled fireplaces, inserts, stoves, facings, outdoor fire pits and fire tables, and accessories. The company's products are sold through independent dealers, distributors, eCommerce retailers, wholesalers, and retail outlets. A majority of the firm's revenue is generated from the Workplace furnishings segment. Geographically, it operates in the United States.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.